TD Cowen Maintains Hold on Novavax, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Brendan Smith maintains a Hold rating on Novavax (NASDAQ:NVAX) and raises the price target from $5 to $10.
May 13, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen's updated Hold rating and increased price target from $5 to $10 for Novavax reflects a cautiously optimistic outlook.
The increase in price target by TD Cowen suggests a positive reassessment of Novavax's value, potentially leading to increased investor interest and a positive short-term price movement. The Hold rating indicates a view that the stock is currently valued appropriately, but the raised target implies expectations of future growth or stabilization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100